DK1272207T3 - Anvendelse af et botulinustoksin til fremstilling af et lægemiddel til perifer indgivelse til behandling af smerte, der ikke står i forbindelse med muskelspasme eller hovedpine - Google Patents

Anvendelse af et botulinustoksin til fremstilling af et lægemiddel til perifer indgivelse til behandling af smerte, der ikke står i forbindelse med muskelspasme eller hovedpine

Info

Publication number
DK1272207T3
DK1272207T3 DK01924939T DK01924939T DK1272207T3 DK 1272207 T3 DK1272207 T3 DK 1272207T3 DK 01924939 T DK01924939 T DK 01924939T DK 01924939 T DK01924939 T DK 01924939T DK 1272207 T3 DK1272207 T3 DK 1272207T3
Authority
DK
Denmark
Prior art keywords
headache
pain
drug
manufacture
treatment
Prior art date
Application number
DK01924939T
Other languages
English (en)
Inventor
Kei Roger Aoki
Minglei Cui
Stephen Jenkins
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24196890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1272207(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1272207T3 publication Critical patent/DK1272207T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK01924939T 2000-04-14 2001-04-11 Anvendelse af et botulinustoksin til fremstilling af et lægemiddel til perifer indgivelse til behandling af smerte, der ikke står i forbindelse med muskelspasme eller hovedpine DK1272207T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/550,371 US6464986B1 (en) 2000-04-14 2000-04-14 Method for treating pain by peripheral administration of a neurotoxin
PCT/US2001/011836 WO2001078760A2 (en) 2000-04-14 2001-04-11 Method for treating pain by peripheral administration of a neurotoxin

Publications (1)

Publication Number Publication Date
DK1272207T3 true DK1272207T3 (da) 2007-09-10

Family

ID=24196890

Family Applications (6)

Application Number Title Priority Date Filing Date
DK05006625.7T DK1604681T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinustoksin til behandling af ledsmerte
DK05006622.4T DK1604678T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinumtoksin ved behandlingen af postoperativ smerte
DK05006623.2T DK1604679T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinumtoksin ved behandlingen af viskeral smerte
DK05006627.3T DK1576963T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinustoxin til behandling af en af infektion forårsaget smerte
DK01924939T DK1272207T3 (da) 2000-04-14 2001-04-11 Anvendelse af et botulinustoksin til fremstilling af et lægemiddel til perifer indgivelse til behandling af smerte, der ikke står i forbindelse med muskelspasme eller hovedpine
DK05006624.0T DK1604680T3 (da) 2000-04-14 2001-04-11 Anvendelse af butulinumtoksin ved behandlingen af neuralgisk smerte

Family Applications Before (4)

Application Number Title Priority Date Filing Date
DK05006625.7T DK1604681T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinustoksin til behandling af ledsmerte
DK05006622.4T DK1604678T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinumtoksin ved behandlingen af postoperativ smerte
DK05006623.2T DK1604679T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinumtoksin ved behandlingen af viskeral smerte
DK05006627.3T DK1576963T3 (da) 2000-04-14 2001-04-11 Anvendelse af botulinustoxin til behandling af en af infektion forårsaget smerte

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05006624.0T DK1604680T3 (da) 2000-04-14 2001-04-11 Anvendelse af butulinumtoksin ved behandlingen af neuralgisk smerte

Country Status (19)

Country Link
US (14) US6464986B1 (da)
EP (7) EP1576963B1 (da)
JP (1) JP4037652B2 (da)
KR (1) KR20030009431A (da)
CN (1) CN1188165C (da)
AR (1) AR030209A1 (da)
AT (6) ATE364393T1 (da)
AU (2) AU5154601A (da)
BR (1) BR0110030A (da)
CA (3) CA2485919A1 (da)
CY (2) CY1108065T1 (da)
DE (6) DE60142590D1 (da)
DK (6) DK1604681T3 (da)
ES (7) ES2287117T3 (da)
MX (1) MXPA02009932A (da)
NZ (1) NZ521535A (da)
PT (2) PT1604680E (da)
TW (1) TWI282282B (da)
WO (1) WO2001078760A2 (da)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6977080B1 (en) 1999-08-10 2005-12-20 Allergan, Inc. Intrapericardial botulinum toxin treatment for bradycardia
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
WO2002000172A2 (en) * 2000-06-28 2002-01-03 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US20040219619A1 (en) * 2000-07-21 2004-11-04 Ester Fernandez-Salas Methods of identifying compounds that alter toxin persistence and/or protease activity
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US7691983B2 (en) 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
ITUD20010002A1 (it) * 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
WO2003047589A1 (en) * 2001-11-15 2003-06-12 Micro Algae Corporation Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
JP2005538983A (ja) * 2002-07-19 2005-12-22 メステックス アクチエンゲゼルシャフト 関節痛の治療のための薬剤を製造するための神経毒性物質の使用および同薬剤を適用する方法
JP2006513994A (ja) * 2002-10-15 2006-04-27 アラーガン、インコーポレイテッド ボツリヌス毒素歯科治療および歯科措置
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
US7238357B2 (en) * 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
EP1599213A4 (en) * 2003-02-24 2009-07-15 Ira Sanders CELL MEMBRANE TRANSLOCATION OF SNARE R GUL S INHIBITORS, ASSOCIATED COMPOSITIONS AND PATHOLOGY TREATMENT PROCESSES
EP1599220B1 (en) * 2003-03-06 2013-07-17 Botulinum Toxin Research Associates, Inc. Selection of patients with increased responsiveness to botulinum toxin
AU2004216901B2 (en) * 2003-03-06 2009-11-12 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin
ES2381091T3 (es) * 2003-03-06 2012-05-23 Botulinum Toxin Research Associates, Inc. Tratamiento del dolor facial crónico y cefalea relacionados con la sinusitis con toxina botulínica
GB2400316A (en) * 2003-04-10 2004-10-13 Richard Markoll Electromagnetic stimulation in patients with osteoporosis
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US7390496B2 (en) * 2003-04-25 2008-06-24 Allergan, Inc. Therapeutic treatments for repetitive hand washing
US7393538B2 (en) * 2003-04-25 2008-07-01 Ackerman Alan H Clostridial toxin treatment for dermatillomania
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US20050148935A1 (en) * 2003-12-29 2005-07-07 Rozalina Dimitrova Botulinum toxin injection guide
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US6974579B2 (en) * 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
JP2007538010A (ja) * 2004-05-07 2007-12-27 ファイトトックス リミテッド フィコトキシンの経皮投与
WO2005110417A1 (en) * 2004-05-07 2005-11-24 Phytotox Limited Phycotoxins and uses thereof
KR100668570B1 (ko) * 2004-06-28 2007-01-16 입센 리미티드 복재신경 포착에 의한 무릎 관절 통증 치료를 위한,보툴리눔 독소를 포함하는 제약 조성물
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
GB2417419A (en) * 2004-07-12 2006-03-01 Ipsen Ltd Therapeutic use of Botulinum toxin
US20060024794A1 (en) * 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
EP1982997B1 (en) 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
US7429386B2 (en) * 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US8343929B2 (en) 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
PT1802339E (pt) 2004-09-23 2011-12-15 Toxcure Inc Tratamento de neoplasmas com neurotoxina
US20060073208A1 (en) 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US7897147B2 (en) * 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
WO2006096163A1 (en) 2005-03-03 2006-09-14 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
EP1871789B1 (en) 2005-03-15 2013-11-06 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
ES2351942T3 (es) 2005-04-05 2011-02-14 Allergan Inc Analisis de la actividad de una toxina clostridial.
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US20060269574A1 (en) * 2005-05-31 2006-11-30 De Beer Johann F Method of repairing tendons by surgery
CA2948238A1 (en) * 2005-06-14 2006-12-28 Revance Therapeutics, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
BRPI0613631A8 (pt) * 2005-07-18 2017-12-26 Univ Massachusetts Lowell nanoemulsão e método,
US7910116B2 (en) * 2005-08-24 2011-03-22 Allergan, Inc. Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
BRPI0619134B8 (pt) 2005-12-01 2021-05-25 Univ Massachusetts Lowell nanoemulsão, composição farmacêutica, composição, métodos cosméticos para o tratamento de rugas, linhas faciais e/ou linhas do pescoço, e de retardar o início das rugas, linhas faciais e/ou linhas do pescoço, e, método de fabricação de uma nanoemulsão
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20070178121A1 (en) * 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
US7794386B2 (en) 2006-03-15 2010-09-14 Allergan, Inc. Methods for facilitating weight loss
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
US7811586B2 (en) * 2006-05-02 2010-10-12 Allergan, Inc. Methods for alleviating testicular pain
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US20080092910A1 (en) * 2006-10-18 2008-04-24 Allergan, Inc. Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
FR2907680B1 (fr) * 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
WO2008070538A2 (en) * 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
SG10201607909WA (en) * 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
ES2520765T3 (es) 2007-02-15 2014-11-11 Allergan, Inc. Uso de toxina botulínica para el tratamiento de hiperhidrosis
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
DE102007038015A1 (de) * 2007-08-10 2009-02-19 Hefter, Harald, Prof. Dr. med. Dr. rer. nat. Verwendung eines Neurotoxins
JP2009132672A (ja) * 2007-10-31 2009-06-18 Okayama Univ ボツリヌス毒素由来のポリペプチドを有効成分として含む鎮痛作用を有する医薬組成物
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) * 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
MX379265B (es) * 2008-06-26 2025-03-11 Anterios Inc Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
US20100028385A1 (en) * 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
WO2010016901A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type b (150 kd)
WO2010016895A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type b
WO2010051039A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type b
WO2010051038A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type b (150 kd)
US20120021969A1 (en) 2009-03-06 2012-01-26 Allergan, Inc. Prosthetic implant shell
WO2011038015A1 (en) 2009-09-24 2011-03-31 Allergan, Inc. Method of treating osteoporosis with a neurotoxin
CN102892454B (zh) 2010-01-26 2016-01-20 迈克尔·A·埃文斯 用于去神经支配的方法、装置以及药剂
JP2011157331A (ja) * 2010-02-03 2011-08-18 Chemo-Sero-Therapeutic Research Inst 高用量投与が可能なボツリヌス毒素製剤
US20120195878A1 (en) 2011-01-28 2012-08-02 Allergan, Inc. Protocol for the administration of botulinum toxins
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
US8992941B2 (en) 2011-07-08 2015-03-31 Allergan, Inc. Method for treatment of esophageal spasm
WO2013009625A1 (en) 2011-07-08 2013-01-17 Allergan, Inc. Method for treatment of autonomic nervous system disorders
CN103813802A (zh) 2011-07-14 2014-05-21 阿勒根公司 用于治疗与性活动相关的失禁的方法
AU2012283968B2 (en) 2011-07-20 2016-04-14 Allergan, Inc. Botulinum toxins for use in a method for treatment of adipose deposits
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2836193B1 (en) 2012-04-13 2018-01-31 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (ii)
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
BR112015024221A2 (pt) 2013-03-22 2017-07-18 Lipotec Sa exopolissacarídeo, uso do exopolissacarídeio, e, composição cosmética ou dermofarmacêutica
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10149893B2 (en) 2013-09-24 2018-12-11 Allergan, Inc. Methods for modifying progression of osteoarthritis
US9480731B2 (en) 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2016040039A1 (en) * 2014-09-12 2016-03-17 Allergan, Inc. Methods for treating osteoarthritis pain
CN107108703B (zh) 2015-01-09 2022-09-23 益普生生物创新有限公司 阳离子神经毒素
JP7097070B2 (ja) 2015-10-01 2022-07-07 ゴレイニ インコーポレイテッド クロライドチャネルの標的発現及びその使用方法
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US11623000B2 (en) 2017-05-24 2023-04-11 Atgc Co., Ltd. Pharmaceutical composition for treating foot pain disease including botulinum toxin and hyaluronic acid, and foot pain disease treatment method using same
EP3470054B1 (en) 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
WO2019162696A1 (en) 2018-02-26 2019-08-29 Ipsen Biopharm Limited Use of ultrasound to guide injection of non-cytotoxic protease
CN112165955A (zh) 2018-05-21 2021-01-01 益普生生物制药有限公司 抑制骨癌引起的异常性疼痛
LT3660509T (lt) 2018-11-29 2022-05-10 Hugel Inc. Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti
GB202011055D0 (en) * 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
JP2025534349A (ja) 2022-09-30 2025-10-15 イプセン バイオファーム リミテッド 膀胱痛症候群の治療
CN119258202A (zh) 2023-07-05 2025-01-07 重庆誉颜制药有限公司 一种肉毒毒素蛋白组合物及其应用
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693207B1 (fr) * 1992-07-03 1994-09-30 Orsan Souche de levure permettant la co-expression d'une activité mono-oxygénase de cytochrome P450 hétérologue et d'une NADPH-cytochrome P450-réductase endogène ou hétérologue et son utilisation à des fins de bioconversion.
JP4381477B2 (ja) 1993-01-15 2009-12-09 ボツリヌム トキシン リサーチ アソシエイト インコーポレイテッド 筋膜疼痛症候群の治療方法
US5592212A (en) * 1993-04-16 1997-01-07 News Datacom Ltd. Methods and systems for non-program applications for subscriber television
ES2332905T3 (es) * 1993-12-28 2010-02-15 Allergan, Inc. Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
PT1086702E (pt) 1994-05-09 2005-08-31 William J Binder Neurotoxinas pre-sinapticas para tratamento da dor de cabeca devida a enxaqueca
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
JPH08306853A (ja) * 1995-05-09 1996-11-22 Fujitsu Ltd 半導体装置及びその製造方法及びリードフレームの製造方法
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6261572B1 (en) * 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
WO2006017004A1 (en) 2004-07-07 2006-02-16 Obstecare Inc. Method for monitoring a childbirth process

Also Published As

Publication number Publication date
EP1272207B1 (en) 2007-06-13
ATE456375T1 (de) 2010-02-15
EP1272207A2 (en) 2003-01-08
EP1604680B1 (en) 2010-01-27
ES2349782T3 (es) 2011-01-11
ES2338238T3 (es) 2010-05-05
ES2353878T3 (es) 2011-03-07
CA2406367A1 (en) 2001-10-25
DE60141230D1 (de) 2010-03-18
EP1604681B1 (en) 2010-09-08
DE60142712D1 (de) 2010-09-09
CA2406367C (en) 2008-01-29
DK1604680T3 (da) 2010-05-10
AU2001251546B2 (en) 2004-07-01
DE60143061D1 (de) 2010-10-21
US7291344B2 (en) 2007-11-06
EP1604679B1 (en) 2010-07-28
EP1604678A1 (en) 2005-12-14
ES2347256T3 (es) 2010-10-27
US20060275326A1 (en) 2006-12-07
EP1576963A2 (en) 2005-09-21
US20080138364A1 (en) 2008-06-12
DE60143549D1 (de) 2011-01-05
JP4037652B2 (ja) 2008-01-23
PT1272207E (pt) 2007-06-29
US7294339B2 (en) 2007-11-13
JP2003531127A (ja) 2003-10-21
AU5154601A (en) 2001-10-30
EP1576963A3 (en) 2005-12-07
US20040028706A1 (en) 2004-02-12
US7067137B2 (en) 2006-06-27
DK1604681T3 (da) 2010-11-29
CA2485919A1 (en) 2001-10-25
KR20030009431A (ko) 2003-01-29
AR030209A1 (es) 2003-08-13
DE60142590D1 (de) 2010-08-26
CN1436085A (zh) 2003-08-13
ES2394314T3 (es) 2013-01-30
EP1550456A3 (en) 2005-12-07
ATE475427T1 (de) 2010-08-15
US20060039916A1 (en) 2006-02-23
CY1109972T1 (el) 2014-09-10
US7374769B2 (en) 2008-05-20
CY1108065T1 (el) 2014-02-12
US7211262B2 (en) 2007-05-01
US7361358B2 (en) 2008-04-22
US7172763B2 (en) 2007-02-06
EP1604678B1 (en) 2010-07-14
ES2287117T3 (es) 2007-12-16
DE60128899T2 (de) 2008-02-21
WO2001078760A2 (en) 2001-10-25
ATE364393T1 (de) 2007-07-15
US20050058666A1 (en) 2005-03-17
MXPA02009932A (es) 2004-08-19
US20020176872A1 (en) 2002-11-28
DK1576963T3 (da) 2011-02-21
AU2001251546B9 (en) 2004-12-02
DE60128899D1 (de) 2007-07-26
US6869610B2 (en) 2005-03-22
US7468189B2 (en) 2008-12-23
ATE489102T1 (de) 2010-12-15
DK1604679T3 (da) 2010-10-25
EP1604680A1 (en) 2005-12-14
EP1576963B1 (en) 2010-11-24
ES2347792T3 (es) 2010-11-04
US20040018213A1 (en) 2004-01-29
US20040018214A1 (en) 2004-01-29
US7276245B2 (en) 2007-10-02
US20070014816A1 (en) 2007-01-18
ATE473753T1 (de) 2010-07-15
EP1604681A1 (en) 2005-12-14
US6464986B1 (en) 2002-10-15
US20060275325A1 (en) 2006-12-07
US20040018212A1 (en) 2004-01-29
DK1604678T3 (da) 2010-10-18
EP1550456B1 (en) 2012-09-26
EP1604679A1 (en) 2005-12-14
PT1604680E (pt) 2010-02-11
WO2001078760A3 (en) 2002-03-21
BR0110030A (pt) 2003-06-03
US7288260B2 (en) 2007-10-30
EP1550456A2 (en) 2005-07-06
NZ521535A (en) 2004-09-24
US20050152925A1 (en) 2005-07-14
ATE480253T1 (de) 2010-09-15
CA2485920A1 (en) 2001-10-25
US20060039917A1 (en) 2006-02-23
TWI282282B (en) 2007-06-11
CN1188165C (zh) 2005-02-09

Similar Documents

Publication Publication Date Title
DK1272207T3 (da) Anvendelse af et botulinustoksin til fremstilling af et lægemiddel til perifer indgivelse til behandling af smerte, der ikke står i forbindelse med muskelspasme eller hovedpine
EE200300212A (et) Ravimite kombinatsioonid (näiteks kloorpromasiin ja pentamidiin) neoplastiliste haiguste raviks
DK1250146T3 (da) Anvendelse af botulinumtoxin til behandling af diabetes
DK1196172T3 (da) (S,S)-reboxetin til behandling af kronisk smerte
WO2002028425A3 (en) Methods for treating muscle injuries
DE60204075D1 (de) Nadelloses Subkutaninjektionssystem, Anwendungsvorrichtung und Medikamentenkartusche
DE60014279D1 (de) Stiftförmige Medikamentenspritze
DE60105922D1 (de) Tragbares, autarkes Medikamenteninfusionsgerät
EE04344B1 (et) Telmisartaani polümorfid, meetodid nende valmistamiseks ja nende kasutamine ravimi valmistamiseks
NO20013727D0 (no) Anvendelse av Botulinumtoksin B for fremstilling av et medikament
ITRM910922A0 (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e metodo per applicarla.
EE200200274A (et) Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
ID30116A (id) Turunan-turunan piridopiranoazepin, pembuatannya dan penggunaan terapinya
WO2003030927A3 (fr) Utilisation de peptides analogues de la thymuline (pat) pour la fabrication de medicaments contre la douleur
EE200200214A (et) Dipüridamooli või mopidamooli kasutamine sellise ravimi valmistamiseks, mis on ette nähtud fibriinsõltuvate mikrotsirkulatsiooni häirete ennetamiseksja raviks
EE200300363A (et) N-(püridinüül)-1H-indool-1-amiinühendite kasutamine ravimi valmistamiseks, mis on ette nähtud müeliinikaotusega seotud haiguste ja seisundite ravimiseks
ID26612A (id) Turunan-turunan siklobutena, pembuatannya dan penggunaan-penggunaan terapinya
EP1440689A3 (en) Treatment of neurotic disorders
DK1206257T3 (da) Anvendelse af aminosyrer til fremstilling af lægemidler, der er beregnet til behandling af insulinresistens
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
WO2003008637A3 (en) Use of genotyping in the individualization of therapy
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
NO20032006L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
UY26990A1 (es) Nuevas composiciones de medicamentos
EE200200215A (et) 2-amino-3,4-dihüdrokinasoliinide kasutamine ravimi valmistamiseks, mis on ette nähtud isheemilistest seisunditest tingitud haiguste raviks või ennetamiseks